MBMatthew I. Bellgard

Matthew I. Bellgard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew I. Bellgard has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toileting Problems and Associated Factors in Adults Enrolled in the Global Angelman Syndrome Registry

    by Emma Walsh, Arlene Mannion, Sally Whelan, Evan Flynn, Megan Tones, Helen Heussler, Matthew Bellgard, Geraldine Leader

    Background: Angelman Syndrome (AS) is a rare neurodevelopmental disorder caused by the lack of expression of the UBE3A gene, which can result from abnormalities of the maternally inherited chromosome 15q11‐q13. The purpose of this study is to investigate the most common types of toileting problems in adults with AS and the associated factors of toileting problems in adults with AS. Method: Data from participants with AS ( N = 40; aged 18–46 years) registered with the Global Angelman Registry, were divided into toileting problems and no toileting problems groups based on the presence or absence of 50% of the toileting behaviours recorded in the registry. Results: It was found that 65% of the sample presented with toileting problems. A significant association between toileting problems and type of feeding during infancy, the use of signing and the use of single words, as a form of communication, were found. Feeding type and use of signing were analysed using a logistic regression and classified 95% of individuals in the sample. Conclusion: The novel findings that this study adds are investigating toileting problems and associated factors of toileting problems in an adult sample of individuals diagnosed with AS. Little research has been conducted on toileting problems in adults with AS. The current study further adds to the small body of literature on toileting problems in adults with AS.

  • Open Access

    Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria

    by Andre Mu, William P. Klare, Sarah L. Baines, C. N. Ignatius Pang, Romain Guérillot, Nichaela Harbison-Price, Nadia Keller, Jonathan Wilksch, Nguyen Thi Khanh Nhu, Minh-Duy Phan, et al.

    Even in the setting of optimal resuscitation in high-income countries severe sepsis and septic shock have a mortality of 20–40%, with antibiotic resistance dramatically increasing this mortality risk. To develop a reference dataset enabling the identification of common bacterial targets for therapeutic intervention, we applied a standardized genomic, transcriptomic, proteomic and metabolomic technological framework to multiple clinical isolates of four sepsis-causing pathogens: Escherichia coli, Klebsiella pneumoniae species complex, Staphylococcus aureus and Streptococcus pyogenes. Exposure to human serum generated a sepsis molecular signature containing global increases in fatty acid and lipid biosynthesis and metabolism, consistent with cell envelope remodelling and nutrient adaptation for osmoprotection. In addition, acquisition of cholesterol was identified across the bacterial species. This detailed reference dataset has been established as an open resource to support discovery and translational research.


  • Design, development and deployment of a web-based patient registry for rare genetic lipid disorders

    by Kathryn R. Napier, Amanda J. Hooper, David M. Ng, Lee Render, Damon A. Bell, Jing Pang, Gerald F. Watts, Matthew I. Bellgard, John R. Burnett


  • Open Access

    Characterization of genome-wide variations induced by gamma-ray radiation in barley using RNA-Seq

    by Cong Tan, Xiao-Qi Zhang, Yin Wang, Dianxin Wu, Matthew I. Bellgard, Yanhao Xu, Xiaoli Shu, Gaofeng Zhou, Chengdao Li

    Background: Artificial mutagenesis not only provides a new approach to increase the diversity of desirable traits for breeding new varieties but are also beneficial for characterizing the genetic basis of functional genes. In recent decades, many mutation genes have been identified which are responsible for phenotype changes in mutants in various species includingArabidopsisand rice. However, the mutation feature in induced mutants and the underlying mechanisms of various types of artificial mutagenesis remain unclear.Results: In this study, we adopted a transcriptome sequencing strategy to characterize mutations in coding regions in a barley dwarf mutant induced by gamma-ray radiation. We detected 1193 genetic mutations in gene transcription regions introduced by gamma-ray radiation. Interestingly, up to 97% of the gamma irradiation mutations were concentrated in certain regions in chromosome 5H and chromosome 7H. Of the 26,745 expressed genes, 140 were affected by gamma-ray radiation; their biological functions included cellular and metabolic processes.Conclusion: Our results indicate that mutations induced by gamma-ray radiation are not evenly distributed across the whole genome but located in several concentrated regions. Our study provides an overview of the feature of genetic mutations and the genes affected by gamma-ray radiation, which should contribute to a deeper understanding of the mechanisms of radiation mutation and their application in gene function analysis.


  • Open Access

    RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework

    by Matthew I. Bellgard, Tom Snelling, James M. McGree

    Within the 21 APEC economies alone, there are an estimated 200 million individuals living with a rare disease. As such, health data on these individuals, and hence patient registries, are vital. However, registries can come in many different forms and operating models in different jurisdictions. They possess a varying degree of functionality and are used for a variety of purposes. For instance registries can facilitate service planning as well as underpin public health and clinical research by providing de-identified data to researchers. Furthermore, registries may be used to create and disseminate new knowledge to inform clinical best practice and care, to identify and enrol participants for clinical trials, and to enable seamless integration of patient data for diagnostic testing and cascade screening. Registries that add capability such as capturing patient reported outcomes enable patients, and their carers, to become active partners in their care, rapidly furthering research and ensuring up-to-date practice-based evidence. Typically, a patient registry centres around the notion of health data ‘capture’, usually for only one or a small subset of the functions outlined above, thereby creating fragmented datasets that, despite the best efforts and intentions, make it difficult to exchange the right data for the right purpose to the right stakeholder under appropriate governance arrangements. Trying to incorporate maximum functionality into a registry is an obvious strategy, but monolithic software solutions are not desirable. As an alternative, we propose that it is important to incorporate analytics as core to a patient registry, rather than just utilising registries as a ‘data capture’ solution. We contend that embracing an analytics-centric focus makes it reasonable to imagine a future where it will be possible to evaluate the individual outcomes of health interventions in real time. The purposeful and, importantly, the repurposable application of health data will allow stakeholders to extract, create and reuse knowledge to improve health outcomes, assist clinical decision making, and improve health service design and delivery. To realise this vision, we introduce and describe the concept of a Rare Disease Registry and Analytics Platform (RD-RAP); one that we hope will make a meaningful difference to the lives of those living with a rare disease.


  • Open Access

    Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis

    by Andre Schultz, Julie A. Marsh, Benjamin R. Saville, Richard Norman, Peter G. Middleton, Hugh W. Greville, Matthew I. Bellgard, Scott M. Berry, Tom Snelling

    Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their baseline lung function after pulmonary exacerbations. There is a relative paucity of evidence to inform treatment strategies for exacerbations. Compounding this lack of evidence, there are a large number of treatment options already as well as becoming available. This results in significant variability between medication regimens prescribed by different physicians, treatment centers and regions with potentially adverse impact to patients. The conventional strategy is to undertake essential randomized clinical trials to inform treatment decisions and improve outcomes for patients with exacerbations. However, over the past several decades, clinical trials have generally failed to provide information critical to improved treatment and management of exacerbations. Bayesian adaptive platform trials hold the promise of addressing clinical uncertainties and informing treatment. Using modeling and response adaptive randomization, they allow for the evaluation of multiple treatments across different management domains, and progressive improvement in patient outcomes throughout the course of the trial. Bayesian adaptive platform trials require substantial amounts of preparation. Basic preparation includes extensive stakeholder involvement including elicitation of consumer preferences and clinician understanding of the research topic, defining the research questions, determining the best outcome measures, delineating study sub-groups, in depth statistical modeling, designing end-to-end digital solutions seamlessly supporting clinicians, researchers and patients, constructing randomisation algorithms and importantly, defining pre-determined intra-study end-points. This review will discuss the motivation and necessary steps required to embark on a Bayesian adaptive platform trial to optimize medication regimens for the treatment of pulmonary exacerbations of cystic fibrosis.


  • Open Access

    Differentially expressed genes in response to amitraz treatment suggests a proposed model of resistance to amitraz in R. decoloratus ticks

    by Samantha Baron, Roberto A. Barrero, Michael Black, Matthew I. Bellgard, Elsie M.S. van Dalen, Josephus Fourie, Christine Maritz-Olivier


  • The Expressed Portion of the Barley Genome

    by Craig G. Simpson, Roberto A. Barrero, Micha Bayer, Andrew Flavell, Paulo Rapazote-Flores, Matthew I. Bellgard, Pete E. Hedley, Runxuan Zhang, Robbie Waugh